{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:15:01Z","timestamp":1722888901503},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,3,27]],"date-time":"2009-03-27T00:00:00Z","timestamp":1238112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00106-009-1892-5","type":"journal-article","created":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T05:47:53Z","timestamp":1237960073000},"page":"315-323","source":"Crossref","is-referenced-by-count":0,"title":["Pr\u00e4kanzerosen und fr\u00fchinvasive Karzinome","Precancerous and early invasive carcinomas"],"prefix":"10.1007","volume":"57","author":[{"name":"Dermatologische Klinik Inselspital, Univ. Bern, Schweiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Haneke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Dept. Dermatol., Academisch Ziekenhuis, Univ. Gent, Belgien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Centro Dermatol., Instituto CUF, Porto, Portugal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,27]]},"reference":[{"key":"1892_CR1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2005.01880.x","volume":"30","author":"Graham","year":"2005","unstructured":"Graham GF, Camacho F, Roseborough I et al (2005) Patients with solar keratosis, particularly of the trunk or lower extremities, are at high risk for skin cancer development. Clin Exp Dermatol 30:717\u2013718","journal-title":"Clin Exp Dermatol"},{"key":"1892_CR2","first-page":"335","volume":"16","author":"Quaedvlieg","year":"2006","unstructured":"Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335\u2013339","journal-title":"Eur J Dermatol"},{"key":"1892_CR3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archderm.142.6.729","volume":"142","author":"Morton","year":"2006","unstructured":"Morton C, Horn M, Leman J et al (2006) Comparison of topical methyl levulinate photodynamic with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 142:729\u2013735","journal-title":"Arch Dermatol"},{"key":"1892_CR4","first-page":"629","volume":"2","author":"Smith","year":"2003","unstructured":"Smith S, Piacquadio D, Morhenn V et al (2003) Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2:629\u2013635","journal-title":"J Drugs Dermatol"},{"key":"1892_CR5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2133.2006.07616.x","volume":"156","author":"Perrett","year":"2007","unstructured":"Perrett CM, McGregor JM, Warwick J et al (2007) Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 156:320\u2013328","journal-title":"Br J Dermatol"},{"key":"1892_CR6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","volume":"24","author":"Loven","year":"2002","unstructured":"Loven K, Stein L, Furst K et al (2002) Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990\u20131000","journal-title":"Clin Ther"},{"key":"1892_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2007.11.037","volume":"353","author":"Paolino","year":"2008","unstructured":"Paolino D, Cosco D, Muzzalupo R et al (2008) Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 353:233\u2013242","journal-title":"Int J Pharm"},{"key":"1892_CR8","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/01.cad.0000231479.30524.0e","volume":"17","author":"Saif","year":"2006","unstructured":"Saif MW, Hashmi S, Mattison L et al (2006) Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anticancer Drugs 17:1095\u20131098","journal-title":"Anticancer Drugs"},{"key":"1892_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/1011-1344(92)85108-7","volume":"14","author":"Kennedy","year":"1992","unstructured":"Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14:275\u2013292","journal-title":"J Photochem Photobiol B"},{"key":"1892_CR10","unstructured":"Haneke E (2005) Photodynamic therapy for scarless removal of multiple facial precanceroses and superficial carcinomas. In Bosniak S, Cantisano-Zilkha M (eds) Minimally invasive techniques of oculofacial rejuvenation. Thieme, New York, Stuttgart 151\u2013157"},{"key":"1892_CR11","doi-asserted-by":"crossref","unstructured":"Haneke E (2009) Photodynamic treatment. In Cantisano-Zilkha M, Haddad M (eds) Aesthetic Oculofacial Rejuvenation. Elsevier, New York (in press)","DOI":"10.1016\/B978-0-7020-3365-0.00006-6"},{"key":"1892_CR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.jid.5700048","volume":"126","author":"Angell-Petersen","year":"2006","unstructured":"Angell-Petersen E, Sorensen R, Warloe T et al (2006) Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 126:265\u2013271","journal-title":"J Invest Dermatol"},{"key":"1892_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.det.2006.09.006","volume":"25","author":"Kalisiak","year":"2007","unstructured":"Kalisiak MS, Rao J (2007) Photodynamic therapy for actinic keratoses. Dermatol Clin 25:15\u201323","journal-title":"Dermatol Clin"},{"key":"1892_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.det.2006.09.005","volume":"25","author":"Blume","year":"2007","unstructured":"Blume JE, Oseroff AR (2007) Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 25:5\u201314","journal-title":"Dermatol Clin"},{"key":"1892_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.140.1.33","volume":"140","author":"Touma","year":"2004","unstructured":"Touma D, Yaar M, Whitehead S et al (2004) A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 140:33\u201340","journal-title":"Arch Dermatol"},{"key":"1892_CR16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/lsm.20488","volume":"39","author":"Christiansen","year":"2007","unstructured":"Christiansen K, Bjerring P, Troilius A (2007) 5-ALA for photodynamic photorejuvenation--optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med 39:302\u2013310","journal-title":"Lasers Surg Med"},{"key":"1892_CR17","first-page":"568","volume":"10","author":"Ceburkov","year":"2000","unstructured":"Ceburkov O, Gollnick H (2000) Photodynamic therapy in dermatology. Eur J Dermatol 10:568\u2013575 (disc 576)","journal-title":"Eur J Dermatol"},{"key":"1892_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00042728-200801000-00001","volume":"34","author":"Tull","year":"2008","unstructured":"Tull S, Nunley K, Sengelmann R (2008) Nonsurgical treatment modalities for primary cutaneous malignancies. Dermatol Surg 34:1\u201314","journal-title":"Dermatol Surg"},{"key":"1892_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2006.06.006","volume":"56","author":"Braathen","year":"2007","unstructured":"Braathen LR, Szeimies RM, Basset-Seguin N et al (2007) Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology 2005. J Am Acad Dermatol 56:125\u2013143","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1365-2133.2006.07470.x","volume":"155","author":"Morton","year":"2006","unstructured":"Morton C, Campbell S, Gupta G et al (2006) Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 155:1029\u20131036","journal-title":"Br J Dermatol"},{"key":"1892_CR21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0190-9622(99)70114-3","volume":"41","author":"Kurwa","year":"1999","unstructured":"Kurwa HA, Yong-Gee SA, Seed PT et al (1999) A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 41:414\u2013418","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR22","first-page":"319","volume":"137","author":"Morton","year":"2001","unstructured":"Morton CA, Whitehurst C, McColl JH et al (2001) Photodynamic therapy for large or multiple patches of Bowen\u2019s disease and basal cell carcinoma. Arch Dermatol 137:319\u2013324","journal-title":"Arch Dermatol"},{"key":"1892_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2006.09.009","volume":"25","author":"Morton","year":"2007","unstructured":"Morton CA (2007) Methyl aminolevulinate: actinic keratoses and Bowen\u2019s disease. Dermatol Clin 25:81\u201387","journal-title":"Dermatol Clin"},{"key":"1892_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archderm.134.2.207","volume":"134","author":"Fritsch","year":"1998","unstructured":"Fritsch C, Goerz G, Ruzicka T (1998) Photodynamic therapy in dermatology. Arch Dermatol 134:207\u2013214","journal-title":"Arch Dermatol"},{"key":"1892_CR25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2133.2005.06484.x","volume":"152","author":"Vinciullo","year":"2005","unstructured":"Vinciullo C, Elliott T, Francis D et al (2005) Photodynamic therapy with topical methyl aminolaevulinate for \u201adifficult-to-treat\u2018 basal cell carcinoma. Br J Dermatol 152:765\u2013772","journal-title":"Br J Dermatol"},{"key":"1892_CR26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1365-2133.2003.05600.x","volume":"149","author":"Horn","year":"2003","unstructured":"Horn M, Wolf P, Wulf HC et al (2003) Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 149:1242\u20131249","journal-title":"Br J Dermatol"},{"key":"1892_CR27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.sder.2007.12.001","volume":"27","author":"MacCormack","year":"2008","unstructured":"MacCormack MA (2008) Photodynamic therapy in dermatology: An update on applications and outcomes. Sem Cut Med Surg 27:52\u201362","journal-title":"Sem Cut Med Surg"},{"key":"1892_CR28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2006.02197.x","volume":"31","author":"Rawlins","year":"2006","unstructured":"Rawlins J, Platt A, Gowda P (2006) Regression of BCC following immunosuppression withdrawal in a renal transplant recipient. Clin Exp Dermatol 31:717","journal-title":"Clin Exp Dermatol"},{"key":"1892_CR29","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2165\/00003495-200666130-00001","volume":"66","author":"Woodmansee","year":"2006","unstructured":"Woodmansee C, Pillow J, Skinner RB Jr (2006) The role of topical immune response modifiers in skin cancer. Drugs 66:1657\u20131664","journal-title":"Drugs"},{"key":"1892_CR30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/B:APPT.0000025805.55340.c3","volume":"9","author":"Sch\u00f6n","year":"2004","unstructured":"Sch\u00f6n MP, Sch\u00f6n M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9:291\u2013298","journal-title":"Apoptosis"},{"key":"1892_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","volume":"27","author":"Stanley","year":"2002","unstructured":"Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571\u2013577","journal-title":"Clin Exp Dermatol"},{"key":"1892_CR32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","volume":"126","author":"Hadley","year":"2006","unstructured":"Hadley G, Derry S, Moore RA (2006) Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 126:1251\u20131255","journal-title":"J Invest Dermatol"},{"key":"1892_CR33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","volume":"140","author":"Stockfleth","year":"2004","unstructured":"Stockfleth E, Christophers E, Benninghoff B et al (2004) Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 140:1542","journal-title":"Arch Dermatol"},{"key":"1892_CR34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","volume":"44","author":"Marks","year":"2001","unstructured":"Marks R, Gebauer K, Shumack S et al (2001) Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44:807\u2013813","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","volume":"47","author":"Geisse","year":"2002","unstructured":"Geisse JK, Rich P, Pandya A et al (2002) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47:390\u2013398","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","volume":"138","author":"Shumack","year":"2002","unstructured":"Shumack S, Robinson J, Kossard S et al (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138:1165\u20131171","journal-title":"Arch Dermatol"},{"key":"1892_CR37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1468-3083.2006.01579.x","volume":"20","author":"Ferreres","year":"2006","unstructured":"Ferreres JR, Macaya A, Jucgla A et al (2006) Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 20:877\u2013878","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1892_CR38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2230.28.s1.5.x","volume":"28","author":"Kossard","year":"2003","unstructured":"Kossard S (2003) Treatment of large facial Bowen\u2019s disease: case report. Clin Exp Dermatol 28(Suppl 1):13\u201315","journal-title":"Clin Exp Dermatol"},{"key":"1892_CR39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00042728-200503000-00024","volume":"31","author":"Martin-Garcia","year":"2005","unstructured":"Martin-Garcia RF (2005) Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 31:371\u2013374","journal-title":"Dermatol Surg"},{"key":"1892_CR40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1365-2133.2000.03787.x","volume":"143","author":"Ahmed","year":"2000","unstructured":"Ahmed I, Berth-Jones J (2000) Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143:843\u2013845","journal-title":"Br J Dermatol"},{"key":"1892_CR41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archderm.139.7.944","volume":"139","author":"Epstein","year":"2003","unstructured":"Epstein E (2003) Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 139:944\u2013945","journal-title":"Arch Dermatol"},{"key":"1892_CR42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archderm.139.7.943","volume":"139","author":"Chapman","year":"2003","unstructured":"Chapman MS, Spencer SK, Brennick JB (2003) Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 139:943\u2013944","journal-title":"Arch Dermatol"},{"key":"1892_CR43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-4632.2005.02582.x","volume":"44","author":"Ray","year":"2005","unstructured":"Ray CM, Kluk M, Grin CM et al (2005) Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 44:428\u2013434","journal-title":"Int J Dermatol"},{"key":"1892_CR44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-4632.2006.02829.x","volume":"45","author":"Rosen","year":"2006","unstructured":"Rosen T (2006) Limited extent AIDS-related cutaneous Kaposi\u2019s sarcoma responsive to imiquimod 5% cream. Int J Dermatol 45:854\u2013856","journal-title":"Int J Dermatol"},{"key":"1892_CR45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaad.2007.11.005","volume":"58","author":"Schartz","year":"2008","unstructured":"Schartz NEC et al (2008) Imiquimod 5% cream for treatment of HIV-negative Kaposi\u2019s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 58:585\u2013591","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR46","first-page":"708","volume":"4","author":"Li","year":"2005","unstructured":"Li VW, Li WW, Talcott KE, Zhai AW (2005) Imiquimod as an antiangiogenic agent. J Drugs Dermatol 4:708\u2013717","journal-title":"J Drugs Dermatol"},{"key":"1892_CR47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2133.2004.06214.x","volume":"151","author":"Nijisten","year":"2004","unstructured":"Nijisten T, Colpaert CG, Vermeulen PB et al (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 151:837\u2013845","journal-title":"Br J Dermatol"},{"key":"1892_CR48","first-page":"380","volume":"32","author":"Stashower","year":"2006","unstructured":"Stashower ME (2006) Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg 32:380\u2013386","journal-title":"Dermatol Surg"},{"key":"1892_CR49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaad.2006.06.031","volume":"55","author":"Ondo","year":"2006","unstructured":"Ondo AL, Mings SM, Pestak RM, Shanler SD (2006) Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 55:1104\u20131106","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR50","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archderm.139.7.945","volume":"139","author":"Fisher","year":"2003","unstructured":"Fisher GH, Lang PG (2003) Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 139:945\u2013947","journal-title":"Arch Dermatol"},{"key":"1892_CR51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1440-0960.2006.00269.x","volume":"47","author":"Goh","year":"2006","unstructured":"Goh MS (2006) Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 47:186\u2013188","journal-title":"Australas J Dermatol"},{"key":"1892_CR52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaad.2006.10.034","volume":"56","author":"Metcalf","year":"2007","unstructured":"Metcalf S, Crowson AN, Naylor M et al (2007) Imiquimod as an antiaging agent. J Am Acad Dermatol 56:422\u2013425","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2230.2006.02175.x","volume":"31","author":"Mendon\u00e7a","year":"2006","unstructured":"Mendon\u00e7a CO, Yates VM (2006) Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol 31:721","journal-title":"Clin Exp Dermatol"},{"key":"1892_CR54","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2003.09.052","volume":"22","author":"Thomsen","year":"2004","unstructured":"Thomsen LL, Topley P, Daly MG et al (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799\u20131809","journal-title":"Vaccine"},{"key":"1892_CR55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/djg016","volume":"95","author":"Sch\u00f6n","year":"2003","unstructured":"Sch\u00f6n M, Bong AB, Drewniok C et al (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138\u20131149","journal-title":"J Natl Cancer Inst"},{"key":"1892_CR56","first-page":"1306","volume":"60","author":"Masferrer","year":"2000","unstructured":"Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306\u20131311","journal-title":"Cancer Res"},{"key":"1892_CR57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1610-0387.2006.05906.x","volume":"4","author":"Huyke","year":"2006","unstructured":"Huyke C, Laszczyk M, Scheffler A et al (2006) Behandlung aktinischer Keratosen mit Birkenkorkextrakt. J Dtsch Dermatol Ges 4:132\u2013137","journal-title":"J Dtsch Dermatol Ges"},{"key":"1892_CR58","first-page":"299","volume":"40","author":"Bollag","year":"1970","unstructured":"Bollag W (1970) Vitamin\u00a0A and vitamin A acid in the prophylaxis and therapy of epithelial tumkors. Int J Vitam Nutr Res 40:299\u2013314","journal-title":"Int J Vitam Nutr Res"},{"key":"1892_CR59","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199912023412312","volume":"341","author":"Peris","year":"1999","unstructured":"Peris K, Fargnoli MC, Chimenti S (1999) Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 341:1767\u20131768","journal-title":"N Engl J Med"},{"key":"1892_CR60","first-page":"562","volume":"12","author":"Calista","year":"2002","unstructured":"Calista D (2002) Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol 12:562\u2013564","journal-title":"Eur J Dermatol"},{"key":"1892_CR61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5070\/D31NW1550F","volume":"12","author":"Gyurova","year":"2006","unstructured":"Gyurova MS, Stancheva MZ, Arnaudova MN et al (2006) Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J 12:25","journal-title":"Dermatol Online J"},{"key":"1892_CR62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0190-9622(97)70328-1","volume":"36","author":"Miller","year":"1997","unstructured":"Miller BH, Shavin JS, Cognetta A et al (1997) Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil\/epinephrine injectable gel. J Am Acad Dermatol 36:72\u201377","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0190-9622(98)70502-X","volume":"38","author":"Kraus","year":"1998","unstructured":"Kraus S, Miller BH, Swinehart JM et al (1998) Intratumoral chemotherapy with fluorouracil\/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol 38:438\u2013442","journal-title":"J Am Acad Dermatol"},{"key":"1892_CR64","first-page":"1150","volume":"29","author":"Morse","year":"2003","unstructured":"Morse LG, Kendrick C, Hooper D et al (2003) Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 29:1150\u20131153 (Diskussion 1153)","journal-title":"Dermatol Surg"},{"key":"1892_CR65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00042728-200501000-00003","volume":"31","author":"Aftergut","year":"2005","unstructured":"Aftergut K, Curry M, Cohen J (2005) Candida antigen in the treatment of basal cell carcinoma. Dermatol Surg 31:16\u201318","journal-title":"Dermatol Surg"},{"key":"1892_CR66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.cco.0000154108.99236.ed","volume":"17","author":"High","year":"2005","unstructured":"High A, Zedan W (2005) Basal cell nevus syndrome. Curr Opin Oncol 17:160\u2013166","journal-title":"Curr Opin Oncol"},{"key":"1892_CR67","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1158\/0008-5472.CAN-04-1393","volume":"64","author":"Athar","year":"2004","unstructured":"Athar M, Li C, Tang X et al (2004) Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 64:7545\u20137552","journal-title":"Cancer Res"},{"key":"1892_CR68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/35023008","volume":"406","author":"Taipale","year":"2000","unstructured":"Taipale J, Chen JK, Cooper MK et al (2000) Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 406:1005\u20131009","journal-title":"Nature"},{"key":"1892_CR69","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4161\/cbt.5.6.2906","volume":"5","author":"Mukherjee","year":"2006","unstructured":"Mukherjee S, Frolova N, Sadlonova A et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5:674\u2013683","journal-title":"Cancer Biol Ther"},{"key":"1892_CR70","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1600-0625.2006.00465.x","volume":"15","author":"So","year":"2006","unstructured":"So PL, Langston AW, Daniallinia N et al (2006) Long-term establishment, characterization and manipulation of cell lines from mouse basal cell carcinoma tumors. Exp Dermatol 15:742\u2013750","journal-title":"Exp Dermatol"},{"key":"1892_CR71","first-page":"96","volume":"14","author":"Tabs","year":"2004","unstructured":"Tabs S, Avci O (2004) Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 14:96\u2013102","journal-title":"Eur J Dermatol"},{"key":"1892_CR72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10384-006-0341-1","volume":"50","author":"Miyazaki","year":"2006","unstructured":"Miyazaki K, Saika S, Yamanaka O et al (2006) Treatment of eyelid epithelial neoplasm by targeting sonic hedgehog signaling: an experimental study. Jpn J Ophthalmol 50:305\u2013311","journal-title":"Jpn J Ophthalmol"},{"key":"1892_CR73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2003.12.097","volume":"314","author":"Nishimaki","year":"2004","unstructured":"Nishimaki H, Kasai K, Kozaki K et al (2004) A role of activated sonic hedgehog signaling for the cellular proliferation of oral squamous cell carcinoma cell line. Biochem Biophys Res Commun 314:313\u2013320","journal-title":"Biochem Biophys Res Commun"},{"key":"1892_CR74","doi-asserted-by":"crossref","first-page":"2359s","DOI":"10.1158\/1078-0432.CCR-05-2537","volume":"12","author":"Liz\u00e9e","year":"2006","unstructured":"Liz\u00e9e G, Radvanyi LG, Overwijk WW, Hwu P (2006) Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 12:2359s\u20132365s","journal-title":"Clin Cancer Res"},{"key":"1892_CR75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1610-0387.2006.05920.x","volume":"4","author":"Becker","year":"2006","unstructured":"Becker JC, Ugurel S, Br\u00f6cker E-B et al (2006) Neue Therapieans\u00e4tze bei der Behandlung von Tumoren: Histondeacetylase-, Methyltransferase- und Proteasominhibitoren. J Dtsch Ges Dermatol 4:108\u2013113","journal-title":"J Dtsch Ges Dermatol"},{"key":"1892_CR76","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/cncr.23521","volume":"112","author":"Langer","year":"2008","unstructured":"Langer CJ (2008) Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112:2635\u20132645","journal-title":"Cancer"},{"key":"1892_CR77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaad.2006.04.014","volume":"55","author":"Francis","year":"2006","unstructured":"Francis SO, Mahlberg MJ, Johnson KR et al (2006) Melanoma chemoprevention. J Am Acad Dermatol 55:849\u2013861","journal-title":"J Am Acad Dermatol"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-009-1892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00106-009-1892-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-009-1892-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T11:34:15Z","timestamp":1633260855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00106-009-1892-5"}},"subtitle":["Nichtchirurgische Behandlung der Haut von Gesicht und Kopf","Non-surgical treatment of head and facial skin"],"short-title":[],"issued":{"date-parts":[[2009,3,27]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s00106-009-1892-5","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"type":"print","value":"0017-6192"},{"type":"electronic","value":"1433-0458"}],"subject":[],"published":{"date-parts":[[2009,3,27]]}}}